Abstract
Genetic, biochemical, and pathological evidence supports that aggregation of amyloid-beta (Aβ) peptide into fibrillar structures rich in beta-sheets is implicated as the cause of Alzheimer’s disease. Therefore, an attractive therapeutic strategy is to prevent or alter amyloid-beta aggregation. In this work we examine the effects of the short d-peptides pgklvya, kklvffarrrra, and kklvffa on Aβ aggregation in vitro and toxicity in vivo. These peptides are based on the central hydrophobic region of Aβ (residues 16–20), which is believed to be crucial in Aβ self-association. The effect of peptides on Aβ aggregation was examined by circular dichroism spectroscopy, Thioflavin T fluorescence, and ANS binding assay. Transgenic Caenorhabditis elegans model was used to evaluate the pharmacological effect of d-peptides on Aβ-initiated toxicity. The data suggested that d-peptides are very effective at inhibiting fibrillogenesis of Aβ. Among the three peptides tested, only pgklvya and kklvffa improved survival in the transgenic C. elegans. The activity of these peptides correlates with their ability to inhibit Aβ oligomerization. These suggest that d-peptides should be considered during future design of peptide-based inhibitors of amyloid deposition and toxicity.
Similar content being viewed by others
Introduction
Many systemic and neurodegenerative disorders have been found to be associated with the misfolding and aggregation of specific proteins (Soto et al., 2006; Soto and Estrada, 2008). Alzheimer’s disease (AD) is one such degenerative disorder of the brain, accounting for about 50–70 % of the typical, late-onset cases of dementia (Goedert and Spillantini, 2006). AD is characterized by deterioration of cognitive function and behavioral changes and the wide-spread appearance of intraneuronal neurofibrillary tangles and the extracellular deposition of senile plaques (Hardy, 2006). These plaques are primarily composed of amyloid-beta peptide (Aβ). Genetic and neuropathological studies provide strong evidence for the central role of Aβ peptide in the pathogenesis of AD (Hutton et al., 1998; Annaert and De Strooper, 2002; Taylor et al., 2002; Selkoe, 2004). Aβ is a 39–42 residue peptide derived from the amyloid precursor protein (APP) that is normally cleaved by the proteases β- and γ-secretases (Findeis, 2007). Aβ undergoes aggregation spontaneously and assembles into 6–10 nm diameter fibrils with a cross beta-sheet structure (Harper et al., 1999; Goldsbury et al., 2000). Numerous observations indicate that the aggregation of Aβ into fibrils has neurotoxic effects in cell culture and in vivo (Yankner, 1996; Hartley et al., 1999; Pike et al., 1991, 1993; Lorenzo and Yankner, 1994). However, more recent studies demonstrated that prefibrillar intermediates are also capable of initiating pathogenic events (Lambert et al., 1998; Koo et al., 1999; Hartley et al., 1999; Lansbury, 1999; Ward et al., 2000; Dahlgren et al., 2002; Kayed et al., 2003; Glabe, 2006; Walsh and Selkoe, 2007; Hoozemans et al., 2006). This suggests that targeting a specific step involved in Aβ aggregation might inhibit Aβ neurotoxicity. Considerable research efforts have focused on developing treatments that block the toxicity of Aβ. These include the use of protease inhibitors to prevent Aβ production (Beher and Graham, 2005; Vassar, 2005; Wolfe, 2007), immunization with Aβ antibodies (Solomon, 2004; Petrushina et al., 2007), and use of small molecules and peptides to prevent Aβ aggregation (Weggen et al., 2007; Austen et al., 2008; Rivière et al. 2008; Ladiwala et al., 2011a, b). Previous studies showed that the central hydrophobic region of Aβ (residues 16–20 of Aβ, KLVFF) is crucial for Aβ polymerization (Tjernberg et al., 1996). Based on this study, several groups have designed peptides that modulate Aβ fibrillogenesis and toxicity (Soto et al., 1998; Findeis et al. 1999; Gordon et al., 2001; Lowe et al., 2001). d-amino acid peptides have also been identified as inhibitors of amyloid formation and cytotoxicity of the Aβ peptide (Tjernberg et al., 1997; Blanchard et al., 1997; Chalifour et al., 2003; Wiesehan et al., 2003). The major disadvantage with the use of l-amino acid peptides as inhibitors with respect to d-amino acid peptide is their inactivation by proteolysis (Milton et al., 1992). Taken orally, d-peptides can be absorbed systemically whereas l-peptides must be injected to avoid digestion (Pappenheimer et al., 1994, 1997). In this work, we investigated the potential effectiveness of d-amino acid peptides containing Aβ self-recognition motif (amino acid residues, 16–20) on Aβ aggregation and toxicity. We used an in vitro model of Aβ to show the effects of these peptides on Aβ fibrils as well as oligomers formation while in vivo studies were conducted in transgenic Caenorhabditis elegans model that express the human Aβ42 minigene driven by the unc-54 promoter (strain CL2006), Aβ42 is solely expressed within the body wall muscles, resulting in their paralysis (Wu and Luo, 2005; Link, 2006).
Results
Effects of d-peptides on aggregation/turbidity of Aβ
The aggregation of Aβ42 in the presence of d-peptides was monitored by turbidity measurements as shown in Fig. 1. The absorbance of Aβ42 solution measured at a wavelength of 405 nm was used to estimate the amount of aggregation. Both kklvffa and kklvffarrrra at 1:1 and 1:5 molar ratios showed an increase in turbidity of Aβ solution. However, the presence of pgklvya under similar conditions led to a moderate decrease in the extent of Aβ42 aggregation as compared to peptide incubated alone.
Inhibition of fibril formation
The fibril formation of Aβ was measured by ThT binding on aggregates after incubation of Aβ solution in the presence of the d-peptides as shown in Fig. 2. Incubation of Aβ42 with kklvffarrrra and kklvffa resulted in low ThT fluorescence levels suggesting the lack of fibril formation. Furthermore, pgklvya under similar conditions did not have any significant effect on Aβ42 fibrillization. d-peptides in the absence of Aβ did not show an increase in ThT fluorescence.
ThT-bound Aβ fibril was also visualized by fluorescence microscopy (Ban et al., 2004). Aβ42 incubated in the buffer alone shows fibrils of few micrometers (Fig. 3a). Co-incubation with kklvffarrrra and kklvffa led to the formation of a small number of fibrils (Fig. 3b, d). In contrast, Aβ42 aggregates with pgklvya showed mixed morphology with both fibrils and spherical aggregates (Fig. 3c).
ANS fluorescence
To probe the nature of the interaction between Aβ42 and the d-peptides, bis-ANS was used. bis-ANS is a fluorescent dye which shows an increase in fluorescence intensity and blue-shifting of the emission maximum upon binding to the solvent-exposed hydrophobic surfaces of Aβ aggregates (Stryer 1965; Turner and Brand 1968). As shown in Fig. 4, Aβ in its monomeric form had no effect on ANS fluorescence (Kremer et al., 2000). Incubating Aβ42 samples for 3 days showed an increase in ANS fluorescence intensity and a blue shift of the emission maxima to ~489 nm. The ANS fluorescence intensity of Aβ42 increased remarkably when co-incubated with kklvffa and kklvffarrrra while only a small increase was detected when incubated with pgklvya. This means that kklvffarrrra and kklvffa induce exposure of hydrophobic sites in Aβ.
Circular dichroism absorption spectroscopy studies
Circular dichroism spectroscopy (CD) was used to determine the effects of d-peptides on the secondary structure of amyloid-β peptide (Aβ). Aβ peptide on aging undergoes the conformational transition from the unordered structures (random coil) to the β-sheet conformation and is associated with neurotoxic activity in vitro (Simmons et al., 1994; Gordon et al., 2001). The CD spectrum of monomeric Aβ42 peptide was characterized by a strong negative band in the 195–200 nm region, indicative of a disordered or random coil conformation (Fig. 5). After incubating for 3 days, Aβ42 peptide generates β-sheet conformation with a minimum around 218 nm. On the other hand, after 3 days Aβ42 in the presence of kklvffa, kklvffarrrra, and pgklvya remained in random coil conformation with a small reduction in the intensity of the band at 198 nm.
Effects of d-peptides on soluble aggregates of Aβ (oligomers)
A growing number of reports revealed that the most toxic agent of Aβ is nonfibrillar and oligomeric in nature (Lambert et al., 1998; Walsh et al., 2002; Gong et al., 2003). Therefore, compounds which are able to inhibit their formation helps in reducing Aβ toxicity. Oligomers of Aβ42 were characterized in vitro by silver stain. As shown in Fig. 6, lane 1 represents Aβ42 initial aggregation species. The molecular masses of ~16, ~22 kDa, correspond to oligomers of Aβ42. On the other hand, incubation of Aβ42 with kklvffa and pgklvya inhibits the formation of oligomers, while Aβ42 solution incubated with kklvffarrrra shows bands around ~50 and ~98 kDa representing large oligomeric species.
Survival of transgenic C. elegans fed with d-peptides
Transgenic C. elegans expressing human Aβ42 were employed to study the effects of d-peptides on Aβ toxicity in vivo (Link, 1995; Link et al., 2001). Treatment of the worms with 124 μg/ml kklvffa and 124 μg/ml pgklvya resulted in prolonged survival compared to the control animals (Fig. 7a, b). On the other hand, treatment with 123 μg/ml kklvffarrrra did not have significant effect on survival in nematodes.
Discussion
There is now substantial evidence from genetics and biochemical studies that conversion of a soluble Aβ protein into pre-fibrillar, diffusible assemblies and further fiber formation are a key event in the pathogenesis of AD. Therefore, compounds that interfere with this process may be the viable strategy for therapeutic intervention in AD. Earlier studies indicate that peptide’s chirality is not critical for peptide–peptide interactions (Pritsker et al., 1998). l- and d-peptides derived from type IV collagen bind the α3β1 integrin (Milton RC Milton SC Kent 1992). d-peptides derived from chemokines act as antagonists to CXCR4 receptor, resulting in inhibition of CXCR4-dependent HIV-1 (Zhou et al., 2002). Similarly, both d- and l-form of peptides compete for the same binding site in DnaJ chaperone system (Feifel et al., 1998; Bischofberger et al., 2003). In addition, all-d and all-l conformers of the functional element of alphaA-crystallin did not show marked differences in their chaperone-like activity (Bhattacharyya and Sharma, 2001). Furthermore, peptides in d-forms are known to be more protease resistant and less immunogenic than the respective l-enantiomers, giving them additional therapeutics value. Antimicrobial peptides in d-form showed significant improvements in the therapeutic indices when compared with the l-enantiomers (Chen et al., 2006). In another study, the impairment of learning and memory performance of apolipoprotein E gene knockout mice was attenuated with d-amino acid peptide treatment (Brenneman et al., 2004). d-peptides have also been identified as inhibitors of amyloid formation and cytotoxicity of the Aβ peptide (Blanchard et al., 1997; Wiesehan et al., 2003). d-peptides containing self-recognition motif of the Aβ are more effective in inhibiting fibrillogenesis and reducing the toxicity of Aβ in neurons (Chalifour et al., 2003).
In this study, the aim of the work is to design short synthetic peptides consisting of d-amino acids to investigate their influence on Aβ aggregation and Aβ induced pathological behaviors in transgenic C. elegans model. These peptides were designed from the region of Aβ (amino acid residues, 16–20) that is responsible for its self-association and aggregation (Tjernberg et al., 1996; El-Agnaf et al., 1998). Aggregation processes are affected by hydrophobicity, β-sheet propensity, and charge. Single amino acid substitutions affect the amyloid potential of several peptides and proteins (Otzen et al., 2000; Villegas et al., 2000; Giasson et al., 2001; Chiti et al., 2002, 2003; Tjernberg et al., 2002). Addition of proline, lysine, and arginine in the sequence is to “cap” the aggregation prone region of amyloid-β peptide and impair its aggregating tendency. These residues owing to their very low hydrophobicity, charge, and a β-sheet propensity disfavor protein aggregation (Schobert and Tschessche 1978; Srinivas and Balasubramanian, 1995; Samuel et al., 1997; Shiraki et al., 2002; Reddy et al., 2005).
Results from the ThT and turbidity assays suggested that in addition to the β-sheet aggregate, another type of aggregate is formed in the presence of d-peptides. Peptides kklvffa and kklvffarrrra inhibited Aβ fibril aggregates, but increased Aβ over all aggregations. This means that these peptides actively reduce amyloid fibrils and form insoluble amorphous aggregates. On the other hand, peptide pgklvya had no effect on Aβ fibrillogenesis as observed by ThT. However, in fluorescence images, the presence of spherical aggregates indicates that pgklvya may have triggered another mechanism of assembly of Aβ.
CD spectrum analysis suggested that d-peptides inhibited Aβ to adopt β-sheet conformation. This means that aggregates formed by Aβ in the presence of d-peptides had less ß-sheet content. Partially folded structures are generally the key precursor to protein aggregation (Kelly 1996; Fink 1998). Therefore, the nature of the intermediate state is essential for the understanding of the aggregation pathway. These folded structures are characterized by the presence of solvent-exposed hydrophobic clusters as indicated by ANS binding. Data from the result showed that peptides kklvffarrrra and kklvffa cause conformational change that leads to increased exposure of hydrophobic regions as observed by enhanced ANS binding. Hydrophobic sites are believed to play a major role in protein–protein interaction. This suggests that peptides bind to β-amyloid peptide, leading to additional interaction between the exposed hydrophobic sites, which accelerates assembly of Aβ peptide and forms amorphous aggregates. Several reports have demonstrated that compounds that interfere with Aβ aggregation can exert beneficial effects in vivo, in the mouse model of AD (Zou et al., 2003; Stackman et al., 2003; Yang et al., 2005). In this study, the pharmacological effects of d-amino acid peptides on Aβ-induced toxicity were tested on transgenic C. elegans.
Caenorhabditis elegans is an ideal model organism for useful analysis of the age-associated neurodegeneration because of its available genetic information as well the simple structure of its nervous system. Results from the assays indicate that among the three d-peptides tested, kklvffa and pgklvya prolonged survival in the transgenic Caenorhabditis elegans. The protective effect of these two d-peptides is associated with the inhibition of Aβ oligomeric species. Several studies of Aβ neurotoxicity have focused on the effects of insoluble amyloid fibrils; recent work suggests that accumulation of soluble pre-fibrillar aggregate of Aβ is more toxic to cultured neurons. In addition, a behavioral and morphological alteration found in the transgenic mice model of AD indicates that soluble oligomeric Aβ species can mediate neuronal injury in these animals (Hsia et al., 1999; Mucke et al., 2000). Based on the results, oligomeric species of Aβ is inhibited by pgklvya and kklvffa while kklvffarrrra inhibited (~20 kDa) oligomers but favors the formation of higher order of Aβ oligomers (~50 kDa) reported to be abundant in the AD brain (Gong et al., 2003). This suggests that kklvffarrrra although inhibited Aβ fibrils, did not improve survival in worms. Recently, it is reported that HSP-16.2 (small chaperone protein), which shows significant protection against Aβ toxicity in vivo, is associated with reduction of Aβ oligomeric protein in vitro (Fonte et al., 2008; Wu et al., 2006). In another study, EGb-71 suppresses Aβ toxicity by modulating Aβ oligomeric species (Wu et al., 2006).
Conclusion
In summary, using several methods, the effect of designed d-peptides on the early and later stage of Aβ aggregation was tested. The results suggested that kklvffarrrra and kklvffa are very effective at inhibiting fibrillogenesis of Aβ. Transgenic C. elegans model was used to evaluate the pharmacological effect of d-peptides on Aβ-initiated toxicity. Among the three peptides tested, only pgklvya and kklvffa are capable in improving survival in the transgenic C. elegans. The activity of these peptides correlates with their ability to inhibit toxic smaller oligomers of Aβ generated in the early phase of amyloidogenesis. These suggest that these d-peptides should be considered as potential therapeutics against Alzheimer’s disease.
Materials and methods
Source of chemicals
Dicyclohexylcarbodiimide (DCC) and Hydroxybenzotriazole (HOBt) were obtained from Sigma-Aldrich Chemical Company (St., Louis, Missouri, USA). Pentafluorophenol was obtained from Spectrochem Pvt. Ltd. (Mumbai, India). Pyridine, piperidine, phenol, and acetic anhydride were purchased from SRL (Mumbai, India). Sodium chloride, sodium dihydrogen phosphate, and disodium hydrogen phosphate were purchased from S.D. fine chemicals, India. DMAP (4-dimethylamino pyridine) and ninhydrin were obtained from Merck Chemicals (Mumbai, India). The reagents trifluoroacetic acid, ethane dithiol, and thioanisole were obtained from Aldrich (St., Louis, Missouri, USA) and were used as obtained. The solvent’s N, N-dimethylformamide (DMF), dichloromethane, methanol, ethanol, tetrahydrofuran, ethyl acetate, glycerol, hexane, and diethyl ether were all of A. R grade (Merck chemicals, India, Bombay). Wang resin and 9-fluorenylmethoxycarbonyl amino acids (Fmoc-d and Fmoc-l amino acids) for solid phase peptide synthesis were obtained from Novabiochem (Mumbai, India).
Synthesis of amyloid-β peptide and d-amino acid peptides by solid phase peptide synthesis
Amyloid-beta (Aβ) peptide and d-amino acids peptides were synthesized manually by Fmoc (9-fluorenylmethoxy carbonyl) protocols (Fields and Noble, 1990; Chan and White, 2000). The Wang resin was used as a solid support to build the peptide. Pentafluorophenyl active esters/HOBt esters/anhydrides of N-protected Fmoc amino acids (Fmoc-AA) were used as building units. Completion of coupling was monitored by Kaiser’s test (Kaiser et al., 1970) after each coupling. Piperidine solution (20 %) in DMF was used for deprotection of N-terminal Fmoc group followed by next coupling step. The peptide was cleaved from the resin support using 80–90 % trifluoroacetic acid (TFA) and precipitated in cold ether. Peptide was purified by reverse-phase HPLC on C18 chromatography columns using acetonitrile–water–trifluoroacetic acid gradients. Purity of the peptide was evaluated by Maldi-MS.
Aβ sample preparation
To get a monomeric Aβ42, the lyophilized peptide was solubilized and disaggregated using TFA, TFE/HFIP procedures (Chen and Wetzel, 2001). Then the peptide solution was aliquoted out, and HFIP was removed by evaporation and the peptide film was stored at −80 °C until required. Immediately, prior to use, the peptide was dissolved in a phosphate buffer, pH 7.4, to a required concentration.
Turbidity measurements
A simple way to measure the presence of aggregates in a solution is to determine the turbidity by measuring absorbance. By this method, all aggregations of Aβ were measured in the presence of d-peptides. An increase in turbidity would arise from the formation of large aggregates. Aβ42 at the concentration of 50 μM was incubated in the presence and in the absence of d-peptides for 3 days at 37 °C. At the end of incubation each sample was assayed by turbidity at 405 nm wavelength to estimate the amount of aggregations. All the samples containing d-peptides, background signals were determined by measuring the wavelength at 405 nm of samples containing only d-peptides. The resulting values were then used to correct each of the turbidity readings corresponding to assembly reactions.
Thioflavin T assay
Thioflavin T (ThT) is a benzothiazol salt used to visualize amyloid plaques. Free ThT has excitation and emission maxima at ~350 and ~450 nm. However, upon binding to fibrils, the excitation and emission wavelength change to ~450 and ~485 nm, respectively (Naiki et al., 1989, 1990; LeVine, 1999). A 100 μM solution of ThT was prepared and filtered through a 0.2 μM filter. Aβ42 at the concentration of 50 μM was incubated at 37 °C for 3 days either alone or in the presence of d-peptides. A 10 μl sample from the incubated mixture was added to solutions containing 10 μM ThT in phosphate buffer, pH 7.4, and the ThT fluorescence was measured at λ ex = 450 nm and λ ex = 485 nm using a FluoroLog-3 spectrofluorometer (HORIBA Jobin–Yvon, Edison, New Jersey, US).
Fluorescence microscopy
A fluorescence microscope is a light microscope used to study specimens, which can be made to fluoresce. Aβ42 at the concentration of 50 μM was incubated at 37 °C for 3 days either alone or in the presence of d-peptides. 10 μl samples from the incubated mixture were mixed with 5 μl of 50 μM ThT in phosphate buffer, pH 7.4, and the mixture was placed on a glass slide. The ThT-bound amyloid fibrils were observed with a Lieca DMRXA2 upright microscope equipped with a Leica I3 filter and a Leica DC500 camera (Leica Microsystems, Wetzlar, Germany). Images were collected using either a 10× or 60× oil-immersion lens.
ANS fluorescence
4, 4′-Bis (1-anilinonaphthalene 8-sulfonate) (bis-ANS) is frequently used to demonstrate the presence of partially folded conformations of proteins. Bis-ANS binds to solvent-exposed hydrophobic clusters, resulting in a considerable increase in the ANS fluorescence intensity and in a pronounced blue shift of the fluorescence emission maximum. We measured the change of ANS fluorescence to monitor the gain of structure in amyloid-beta peptide (Aβ) in terms of solvent-exposed hydrophobic clusters upon binding with the d-peptides. Aβ42 at the concentration of 50 μM was incubated for 3 days at 37 °C either alone or in the presence of d-peptides. A 10 μl sample from the incubated mixture was added to a solution containing 5 μM ANS in phosphate buffer, pH 7.4, and the fluorescence was measured using a FluoroLog-3 spectrofluorometer (HORIBA Jobin–Yvon, Edison, New Jersey, US). Emission spectrum was recorded from 400 to 600 nm with excitation at 370 nm.
Circular dichroism measurements
The effects of d-peptides on Aβ42 conformation were determined by CD. Aβ42 at a concentration of 50 μM was incubated either alone or in the presence of d-peptides at a molar ratio of 1:1. A spectrum was acquired on a Jasco Model J-715 spectropolarimeter. Dry purified nitrogen was employed to keep the instrument oxygen free during the experiments. The spectra were obtained using cylindrical fused quartz cells of 1 mm path length. A complete base line was recorded for each measurement using the same cell in which the sample solution had been replaced with pure solvent. The spectropolarimeter was calibrated using ammonium- d10-camphorsulfonate as described by the instrument manufacturers.
CD measurements settings
A spectrum was recorded with 1 nm bandwidth and 0.2 nm step resolution at a scan speed of 100 nm/min over the range of 190–260 nm. The spectrum of the peptides was recorded in phosphate buffer pH 7.4. The circular dichroism data represents average values from at least five to ten separate recordings. The resulting spectrum was smoothened. All spectra were corrected by subtraction of any contribution from buffer and d-peptides.
Preparation of Aβ soluble aggregates (oligomers)
Aβ42 stock solutions were obtained by dissolving the lyophilized peptide in anhydrous dimethyl sulfoxide (DMSO) followed by sonication for 30 s. The oligomerization reaction was initiated by diluting the stock solution in the phosphate buffer, pH 7.4 to a final concentration of 50 μM. The reactions were incubated at 37 °C for 2 days in the absence or in the presence of d-peptides. After incubation, samples were spun at 14,000×g (4 °C for 10 min) and the supernatant samples (10 μl) were electrophoresed at 100 V on a NuPAGE 4–12 % Bis–Tris SDS gel. The presence of Aβ soluble aggregate was confirmed by silver staining, according to manufacturer’s instructions (Fast silver, G-Biosciences, US).
Nematode strain
The muscle-specific Aβ-expressing strain was obtained from the Caenorhabditis Genetics Center. Large scale synchronized populations were prepared by alkaline hypochlorite egg purification and propagation of staged animals on Petri plates containing nematode growth media supplemented with 2 % peptone.
Caenorhabditis elegans survival assay
Age synchronized populations of CL2006 worms were grown on NGM IPTG Amp plates containing either a vehicle or d-peptides. To prevent progeny-production pos-1 bacterial strain was used as the food source. The bacteria colony was grown at 37 °C in LB with 100 μg/ml ampicillin, and then seeded on NGM IPTG Amp plates. All d-peptides were added directly to the Pos-1, and animals were exposed to d-peptides starting from the egg.
Abbreviations
- Aβ:
-
Amyloid beta
- app:
-
Amyloid precursor protein
- AD:
-
Alzheimer’s disease
- ThT:
-
Thioflavin T
- HFIP:
-
Hexafluoroisopropanol
- TFA:
-
Trifluoroacetic acid
- TFE:
-
Trifluoroethanol
- bis-ANS:
-
4,4′-Bis(1-anilinonaphthalene 8-sulfonate)
References
Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer’s disease. Annu Rev Cell Dev Biol 18:25–51
Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, El-Agnaf OM (2008) Designing peptide inhibitors for oligomerization toxicity of Alzheimer’s beta-amyloid peptide. Biochemistry 47:1984–1992
Ban T, Hoshino M, Takahashi S, Hamada D, Hasegawa K, Goto Y (2004) Direct observation of Abeta amyloid fibril growth inhibition. J Mol Biol 344:757–767
Beher D, Graham SL (2005) Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease. Expert Opin Investig Drugs 14:1385–1409
Bhattacharyya J, Sharma KK (2001) Conformational specificity of mini-alphaA crystallin as a molecular chaperone. J Peptide Res 57:428–434
Bischofberger P, Han W, Feifel B, Schonfeld HJ, Christen P (2003) d-peptides as inhibitors of the DnaK/DnaJ/GrpE chaperone system. J Biol Chem 278:19044–19047
Blanchard BJ, Konopka G, Russell M, Ingram VM (1997) Mechanism prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer’s disease. Brain Res 776:40–50
Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I (2004) Protective peptides that are orally active mechanistically nonchiral. J Pharmacol Exp Ther 309:1190–1197
Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boulé M, Sarazin P, Stéa D, Lacombe D, Tremblay P, Gervais F (2003) Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J Biol Chem 278:34874–34881
Chan WC, White PD (2000) F-moc solid phase peptide synthesis a practical approach. Oxford University Press Inc, New York
Chen S, Wetzel R (2001) Solubilization disaggregation of polyglutamine peptides. Protein Sci 10:887–891
Chen Y, Vasil AI, Rehaume L, Mant CT, Burns JL, Vasil ML, Hancock RE, Hodges RS (2006) Comparison of biophysical biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem Biol Drug Des 67:162–173
Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM (2002) Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci USA 99:16419–16426
Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM (2003) Rationalization of the effects of mutations on peptide protein aggregation rates. Nature 424:805–808
Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277:32046–32053
El-Agnaf OMA, Guthrie DJ, Walsh DM, Irvine GB (1998) The influence of the central region containing residues 19–25 on the aggregation properties secondary structure of Alzheimer’s β-amyloid peptide. Eur J Biochem 256:560–569
Feifel B, Schonfeld HJ, Christen P (1998) d-peptide ligands for the co-chaperone DnaJ. J Biol Chem 273:11999–12002
Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Peptide Protein Res 35:161–214
Findeis MA (2007) The role of amyloid beta peptide 42 in Alzheimer’s disease. Pharmacol Ther 116:266–286
Findeis MA, Musso GM, Arico-Muendel CC, Benjamin HW, Hundal AM, Lee JJ, Chin J, Kelley M, Wakefield J, Hayward NJ, Molineaux SM (1999) Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 38:6791–6800
Fink AL (1998) Protein aggregation: folding aggregates inclusion bodies amyloid. Fold Des 3:R9–R23
Fonte V, Kipp DR, Yerg J 3rd, Merin D, Forrestal M, Wagner E, Roberts CM, Link CD (2008) Suppression of in vivo beta-amyloid peptide toxicity by overexpression of the HSP-162 small chaperone protein. J Biol Chem 283:784–791
Giasson BI, Murray IV, Trojanowski JQ, Lee VM (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276:2380–2386
Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27:570–575
Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314:777–781
Goldsbury CS, Wirtz S, Muller SA, Sunderji S, Wicki P, Aebi U, Frey P (2000) Studies on the in vitro assembly of a beta 1–40: implications for the search for a beta fibril formation inhibitors. J Struct Biol 130:217–223
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417–10422
Gordon DJ, Sciarretta KL, Meredith SC (2001) Inhibition of β amyloid(40) fibrillogenesis disassembly of β-amyloid(40) fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 40:8237–8245
Hardy J (2006) A hundred years of Alzheimer’s disease research. Neuron 52:3–13
Harper JD, Wong SS, Lieber CM, Lansbury PT Jr (1999) Assembly of a beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer’s disease. Biochemistry 38:8972–8980
Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes progressive neurotoxicity in cortical neurons. J Neurosci 19:8876–8884
Hoozemans JJ, Chafekar SM, Baas F, Eikelenboom P, Scheper W (2006) Always around never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer’s disease. Curr Med Chem 13:2599–2605
Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Kang H, Kholodenenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci USA 96:3228–3233
Hutton M, Perez-Tur J, Hardy J (1998) Genetics of Alzheimer’s disease. Essays Biochem 33:117–131
Kaiser E, Colescott RL, Bossinger CD, Cook PI (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 34:595–598
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489
Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6:11–17
Koo EH, Lansbury PT Jr, Kelly JW (1999) Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96:9989–9990
Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM (2000) Correlation of β-amyloid aggregate size hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 39:10309–10318
Ladiwala AR, Dordick JS, Tessier PM (2011a) Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem 286(5):3209–3218
Ladiwala AR, Mora-Pale M, Lin JC, Bale SS, Fishman ZS, Dordick JS, Tessier PM (2011b) Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β. ChemBioChem 12(11):1749–1758
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Kraft GA, Klein WL (1998) Diffusible nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453
Lansbury PT Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis disease. Proc Natl Acad Sci USA 96:3342–3344
LeVine H (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T methods. Enzymol 309:274–284
Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92:9368–9372
Link CD (2006) Caenorhabditis elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer’s disease. Exp Gerontol 41:1007–1013
Link CD, Johnson CJ, Fonte V, Paupard M, Hall DH, Styren S, Mathis CA, Klunk WE (2001) Visualization of fibrillar amyloid deposits in living transgenic Caenorhabditis elegans animals using the sensitive amyloid dye X-34. Neurobiol Aging 22:217–226
Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation is inhibited by congo red. Proc Nat Acad Sci USA 91:12243–12247
Lowe TL, Strzelec A, Kiessling LL, Murphy RM (2001) Structure-function relationships for inhibitors of -amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40:7882–7889
Milton RC, Milton SC, Kent SB (1992) Total chemical synthesis of a d-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity. Science 256:1445–1448
Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050–4058
Naiki H, Higuchi K, Hosokawa M, Takeda T (1989) Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye thioflavin T1. Anal Biochem 177:244–249
Naiki H, Higuchi K, Matsushima K, Shimada A, Chen WH, Hosokawa M, Takeda T (1990) Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator thioflavine T. Lab Invest 62:768–773
Otzen DE, Kristensen O, Oliveberg M (2000) Designed protein tetramer zipped together with a hydrophobic Alzheimer homology: a structural clue to amyloid assembly. Proc Natl Acad Sci USA 97:9907–9912
Pappenheimer JR, Dahl CE, Karnovsky ML, Maggio JE (1994) Intestinal absorption excretion of octapeptides composed of d amino acids. Proc Natl Acad Sci USA 91:1942–1945
Pappenheimer JR, Karnovsky ML, Maggio JE (1997) Absorption excretion of undegradable peptides: role of lipid solubility net charge. J Pharmacol Exp Ther 280:292–300
Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG (2007) Alzheimer’s disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci 27:12721–12731
Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 207:367–368
Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13:1676–1687
Pritsker M, Jones P, Blumenthal R, Shai Y (1998) A synthetic all d-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane inhibits HIV-1 envelope glycoprotein-mediated cell fusion. Proc Natl Acad Sci U S A 95:7287–7292
Reddy KRC, Lilie H, Rudolph R, Lange C (2005) l-Arginine increases the solubility of unfolded species of hen egg white lysozyme. Protein Sci 14:929–935
Rivière C, Richard T, Vitrac X, Mérillon JM, Valls J, Monti JP (2008) New polyphenols active on beta-amyloid aggregation. Bioorg Med Chem Lett 18:828–831
Samuel D, Kumar TKS, Jayaraman G, Yang PW, Yu C (1997) Proline is a protein stabilizing solute. Biochem Mol Biol Int 41:235–242
Schobert B, Tschessche H (1978) Unusual solution properties of proline its interaction with proteins. Biochim Biophys Acta 541:270–277
Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s Parkinson’s diseases. Nat Cell Bio 6:1054–1061
Shiraki K, Kudou M, Fujiwara S, Imanaka T, Takagi M (2002) Biophysical effect of amino acids on the prevention of protein aggregation. J Biochem (Tokyo) 132:591–595
Simmons LK, May PC, Tomaselli KJ (1994) Secondary structure of amyloid β-peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 45:373–379
Solomon B (2004) Alzheimer’s disease immunotherapy. Curr Alzheimer Res 1:149–163
Soto C, Estrada LD (2008) Protein misfolding neurodegeneration. Arch Neurol 65:184–189
Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy. Nat Med 4:822–826
Soto C, Estrada L, Castilla J (2006) Amyloids prions the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31:150–155
Srinivas V, Balasubramanian D (1995) Proline is a compatible hydrotrope. Langmuir 11:2830–2833
Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF (2003) Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol 184:510–520
Stryer L (1965) The interaction of a naphthalene dye with apomyoglobin apohemoglobin. A fluorescent probe of non-polar binding sites. J Mol Biol 13:482–495
Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296:1991–1995
Tjernberg LO, Na¨slund J, Lindqvist F, Johansson J, Karlstro¨m AR, Thyberg J, Terenius L, Nordstedt C (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271:8545–8548
Tjernberg LO, Lilliehook C, Callaway DJ, Naslund J, Hahne S, Thyberg J (1997) Controlling amyloid beta-peptide fibril formation with protease- stable ligands. J Biol Chem 272:12601–12605
Tjernberg LO, Hosia W, Bark N, Thyberg J, Johansson J (2002) Charge attraction beta propensity are necessary for amyloid fibril formation from tetrapeptides. J Biol Chem 277:43243–43246
Turner DC, Brand L (1968) Quantitative estimation of protein binding site polarity fluorescence of N-arylaminonapthalenesulfonates. Biochemistry 7:3381–3390
Vassar R (2005) Beta-secretase APP Abeta in Alzheimer’s disease. Subcell Biochem 38:79–103
Villegas V, Zurdo J, Filimonov VV, Aviles FX, Dobson CM, Serrano L (2000) Protein engineering as a strategy to avoid formation of amyloid fibrils. Protein Sci 9:1700–1708
Walsh DM, Selkoe DJ (2007) A beta oligomers—a decade of discovery. J Neurochem 101:1172–1184
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539
Ward RV, Jennings KH, Jepras R, Neville W, Owen DE, Hawkins J, Christie G, Davis JB, George A, Karran EH, Howlett DR (2000) Fractionation characterization of oligomeric protofibrillar fibrillar forms of beta-amyloid peptide. Biochem J 348:137–144
Weggen S, Rogers M, Eriksen J (2007) NSAIDs: small molecules for prevention of Alzheimer’s disease or precursors for future drug development? Trends Pharmacol Sci 28:536–543
Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E (2003) Selection of d-amino-acid peptides that bind to Alzheimer’s disease amyloid peptide abeta1–42 by mirror image phage display. ChemBioChem 4:748–753
Wolfe MS (2007) Gamma-secretase modulators. Curr Alzheimer Res 4:571–573
Wu Y, Luo Y (2005) Transgenic Caenorhabditis elegans as a model in Alzheimer’s research. Curr Alzheimer Res 2:37–45
Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-β-induced pathological behaviors are suppressed by ginkgo biloba extract EGb 761 ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautzchy SA, Cole GM (2005) Curcumin inhibits formation of amyloid β oligomers fibrils binds plaques reduces amyloid in vivo. J Biol Chem 280:5892–5901
Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer’s disease. Neuron 16:921–932
Zhou N, Luo MZW, Luo JS, Fan XJ, Cayabyab M, Hiraoka M, Liu DX, Han XB, Pesavento J, Dong CZ, Wang YL, An J, Kaji H, Sodroski JG, Huang ZW (2002) Exploring the stereochemistry of CXCR4-peptide recognition inhibiting HIV-1 entry with d-peptides derived from chemokines. J Biol Chem 277:17476–17485
Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M (2003) Amyloid beta-protein (Abeta)1–40 protects neurons from damage induced by Abeta1-42 in culture in rat brain. J Neurochem 87:609–619
Acknowledgments
We are thankful to Dr. Asit Baran Mandal, Director, Central Leather Research Institute, Chennai for his kind support for this work. The author thanks the Council of Scientific and Industrial Research (CSIR), India, for the award of Junior and Senior Research Fellowships. We are thankful to Man-Wah Tan, Stanford University for allowing us to do C.elegans work in his lab. We are also thankful to Prof. T. Pradeep, IIT Madras for doing Maldi-MS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jagota, S., Rajadas, J. Synthesis of d-amino acid peptides and their effect on beta-amyloid aggregation and toxicity in transgenic Caenorhabditis elegans . Med Chem Res 22, 3991–4000 (2013). https://doi.org/10.1007/s00044-012-0386-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-012-0386-2